Enfusion Company Leadership
| ENFN Stock | USD 10.36 0.26 2.57% |
Enfusion employs about 1.1 K people. The company is managed by 17 executives with a total tenure of roughly 2572 years, averaging almost 151.0 years of service per executive, having 64.82 employees per reported executive. Analysis of Enfusion's management performance can provide insight into the firm performance.
Enfusion |
Enfusion Management Team Effectiveness
The company has return on total asset (ROA) of 0.0592 % which means that it generated a profit of $0.0592 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0548 %, meaning that it created $0.0548 on every $100 dollars invested by stockholders. Enfusion's management efficiency ratios could be used to measure how well Enfusion manages its routine affairs as well as how well it operates its assets and liabilities.Enfusion Workforce Comparison
Enfusion is rated below average in number of employees category among its peers. The total workforce of Information Technology industry is currently estimated at about 34,270. Enfusion holds roughly 1,102 in number of employees claiming about 3% of equities under Information Technology industry.
The company has Profit Margin (PM) of 0.02 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.06 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.06. Enfusion Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Enfusion insiders, such as employees or executives, is commonly permitted as long as it does not rely on Enfusion's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Enfusion insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Somers Deirdre over three weeks ago Acquisition by Somers Deirdre of 13470 shares of Enfusion subject to Rule 16b-3 | ||
Matthew Campobasso over a month ago Disposition of 674 shares by Matthew Campobasso of Enfusion at 8.95 subject to Rule 16b-3 | ||
Bronwen Bastone over a month ago Disposition of tradable shares by Bronwen Bastone of Enfusion at 8.1 subject to Rule 16b-3 | ||
Bronwen Bastone over two months ago Disposition of 18241 shares by Bronwen Bastone of Enfusion at 8.11 subject to Rule 16b-3 | ||
Leibowitz Lawrence E over two months ago Acquisition by Leibowitz Lawrence E of 1332 shares of Enfusion subject to Rule 16b-3 | ||
Bronwen Bastone over three months ago Acquisition by Bronwen Bastone of 558 shares of Enfusion subject to Rule 16b-3 | ||
Matt Campobasso over three months ago Disposition of 493 shares by Matt Campobasso of Enfusion at 8.95 subject to Rule 16b-3 | ||
Bronwen Bastone over three months ago Disposition of 34059 shares by Bronwen Bastone of Enfusion at 9.55 subject to Rule 16b-3 |
Enfusion Notable Stakeholders
An Enfusion stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Enfusion often face trade-offs trying to please all of them. Enfusion's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Enfusion's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Stephen Dorton | Chief Officer | Profile | |
| Michael Berry | Chief Officer | Profile | |
| Lorelei Skillman | Chief Officer | Profile | |
| Stephen Malherbe | Managing Partner | Profile | |
| Oleg Movchan | Interim Director | Profile | |
| Matthew Campobasso | General Secretary | Profile | |
| Bronwen Bastone | Chief Officer | Profile | |
| Joseph Defeo | Global Production | Profile | |
| Kabir Kohli | MD Services | Profile | |
| Jeff Young | Head Implementation | Profile | |
| Brian Murphy | Investor | Profile | |
| Matt Campobasso | General Counsel | Profile | |
| Ignatius Njoku | Head Relations | Profile | |
| Bradley Herring | Chief Officer | Profile | |
| Neal Pawar | Chief Officer | Profile | |
| Daniel Groman | Chief Officer | Profile | |
| Valeria Gutowski | Chief Officer | Profile |
About Enfusion Management Performance
The success or failure of an entity such as Enfusion often depends on how effective the management is. Enfusion management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Enfusion management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Enfusion management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois. Enfusion Inc operates under SoftwareApplication classification in the United States and is traded on New York Stock Exchange. It employs 892 people.
Enfusion Workforce Analysis
Traditionally, organizations such as Enfusion use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Enfusion within its industry.Enfusion Manpower Efficiency
Return on Enfusion Manpower
| Revenue Per Employee | 158.4K | |
| Revenue Per Executive | 10.3M | |
| Net Income Per Employee | 8.4K | |
| Net Income Per Executive | 544.3K | |
| Working Capital Per Employee | 45K | |
| Working Capital Per Executive | 2.9M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enfusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.